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The role of peritoneal cytology at risk-reducing salpingo-oophorectomy33
(RRSO) in women at increased risk of familial ovarian/tubal cancer34
35
Risk-reducing salpingo-oophorectomy (RRSO) is the mainstay of managing women at36
increased risk of familial ovarian cancer and use of strict surgical protocols with serial37
sectioning of the specimen is increasingly the norm. The role of cytology obtained38
from peritoneal washings has received less attention, with even commentaries by39
some authoritative experts omitting to remark on this point.[1] As a result, practice40
varies among surgeons and institutions, with some published series reporting41
cytological findings at RRSO,[2-4] a number omitting to mention this,[5, 6] and42
recently one suggesting it is not necessary.[7] This is an important issue for clinical43
practice which requires addressing. Cytology is likely to impact management44
decisions if early stage or pre-invasive disease is discovered at RRSO. We present a45
summary of the current literature (Tables-1-3), and put forward the rationale for46
cytology to be included as routine in RRSO protocols.47
Relevant papers were identified through an exhaustive search of the online database48
PubMed, using the search terms ‘RRSO’, ‘salpingo-oophorectomy’, ‘oophorectomy’,49
‘prophylactic salpingo-oophorectomy’, ‘risk reducing’ and ‘BRCA’ in different50
combinations. Additional papers were also identified and included where appropriate51
through examining the reference lists of the initially identified papers. Three initial52
series[8-10] were excluded as they were followed by subsequent papers[11-13] in53
which previously published data had been repeated. Five series were excluded as54
details of occult lesions and stages of disease were not available.[13-17] Of the55
remaining series those reporting early stage/ preinvasive disease are summarised in56
tables 1-3.57
58
1) Potential change in stage and subsequent management:59
Positive cytology can lead to upstaging of Stage I microinvasive disease with60
prognostic and therapeutic implications. In the published literature on RRSO, we61
found 45 cases of stage-1 invasive fallopian tube/ ovarian cancers (Table-1).[3-5]62
These included 5 women who had positive cytology, 16 with negative cytology and63
24 women for whom cytology was not done/ reported. A number of series pre-date the64
use of a serial sectioning of the fallopian tube fimbria (SEE-FIM) protocol[18] and it65
is possible that the true incidence of occult early stage cancers may be higher than66
this.67
68
In five of the 21 (23.8% CI, 8.2, 47.2) who had cytology done, positive findings led to69
upstaging of disease from stage Ia to Ic (Table-1). Four of these five cases were70
invasive fallopian tube cancers. Three of these women received chemotherapy and in71
two of these, where follow up details were available, the disease recurred at 13 and 1772
months. In the remaining two patients, no details were reported (Table 1). Despite the73
microscopic nature of these stage1 invasive lesions, positive cytology may define a74
higher risk cohort with guarded prognosis that requires adjuvant chemotherapy. With75
respect to adjuvant chemotherapy, management of primary fallopian tube cancer is76
generally similar to ovarian cancer and comparable 5 year survival rates have been77
reported for stage1a and Stage1b ovarian and fallopian tube cancers.[19, 20] Decision78
making should be individualised through a multidisciplinary forum. It is our practice79
and that of others to advise adjuvant chemotherapy (carboplatin and paclitaxel) for80
stage 1c (any grade) or high-grade (grade-3) stage1a and stage1b disease.[19] The81
presence of positive cytology would thus affect management of Grade1/2 stage82
1a/stage 1b fallopian tube or ovarian cancers. However, some authorities advocate83
that, chemotherapy should be considered for all stage1 fallopian tube cancers.[21]84
Given the fallopian tube lumen is in direct communication with the peritoneal cavity,85
they propound stage Ia fallopian tube cancer has a higher predisposition for distant86
microscopic spread and is functionally equivalent to stage Ic ovarian cancer.87
Negative cytology was found in 10 stage 1a/1b invasive tubal cancers and six stage 1a88
invasive ovarian cancers at RRSO (Table-1). Adjuvant chemotherapy was given in89
three patients (invasive tubal cancer), not given in five (three tubal and two ovarian90
cancers) and not reported in eight cases. Of these 16 cases, follow-up data was only91
available in three who did not receive chemotherapy and were disease free at 3, 2492
and 30 months (Table-1). Cytology would not have impacted on staging in only two93
of these 16 women, both of whom had disease present on the surface of the ovary/94
tubal serosa.[2, 3]95
96
Details of cytology were unclear or not available for 24 cases. Reports of disease free97
survival ranging from 11 to 46 months is reported for seven of these cases, along with98
three deaths: one from disease at 4 years, and two from breast recurrence (Table-1).99
100
2) In Serous Tubal Intraepithelial Carcinoma (STIC) lesions, positive cytology is101
a possible surrogate for early undetected microinvasive disease and/or102
predictive marker for increased peritoneal cancer risk.103
104
Accumulating evidence driven largely by findings in the high-risk population suggests105
that the cell of origin of a proportion of ovarian/tubal cancers lies outside the ovary, in106
the extrauterine mullerian epithelium, with newer models of ovarian carcinogenesis107
suggesting that the tube is the most favoured site.[22] A continuum of tubal epithelial108
change from a putative precursor lesion (the p53 signature)[23] through carcinoma in109
situ (CIS) or Serous tubal insitu carcinoma (STIC) lesions to early invasive tubal110
carcinoma has been described.[24] It has been postulated that genotoxic injury is more111
likely to lead to progression of these lesions to cancer in women at high risk for112
disease.[24] As the currently favoured nomenclature is ‘STIC’, we subsequently use113
this term (instead of ‘CIS’) for all such lesions reported in the literature. The natural114
history of STIC lesions is yet to be established and the evidence base for managing115
these women is very limited.116
117
Of the 31 reported patients with tubal STIC lesions (Table-2),[3, 4, 18] 10 had positive118
cytology, of whom five received adjuvant chemotherapy (paclitaxel and carboplatin).119
No recurrence has been found in such cases, although the follow-up reported is120
extremely limited (Table-2). In addition, there were three reports of women with121
positive cytology and normal tubal/ovarian histology at RRSO,[5] two of whom122
subsequently received chemotherapy (Table-3). These cases of positive cytology with123
STIC/normal histology may potentially reflect undetected early microinvasive124
peritoneal cancer or an early microinvasive lesion in the tube/ovary missed despite 2-125
3 mm serial sectioning. Additional multistep level sections of tubal and ovarian tissue126
blocks beyond original 2-3 mm standard protocols has been shown to further increase127
detection of occult cancer. The finding of positive cytology at RRSO is consistent128
with pelvic serous cancers arising in the tube and seeding the ovary or peritoneal129
surfaces, as well as cancers which may arise/ be present in the peritoneum, omentum130
or other abdominopelvic structures. We would advocate that consideration be given to131
full staging surgery in women with STIC and positive cytology.132
133
Five of the 18 cases of STIC with negative cytology also received adjuvant134
chemotherapy (paclitaxel and carboplatin) (Table-2). Cytology was not135
undertaken/not reported in three cases. The role of chemotherapy in these cases of136
STIC is not yet well defined and practice varies between institutions. Given the lack of137
clear evidence of benefit it has not been our practice in women with STIC and138
negative cytology to undertake further staging surgery or to routinely give139
chemotherapy, though this has been advocated by others.[3] Although no recurrence140
has been reported in these cases with negative cytology, only limited follow-up data is141
available in 13 cases (Table-2). However, we are aware of an unreported case of142
peritoneal cancer developing in one patient with STIC four years after risk reducing143
surgery (personal communication – Drapkin R). This patient was a BRCA1 carrier144
who had breast cancer at age 34 and a recurrence at age 41. She underwent RRSO at145
the age of 44. Peritoneal cytology was not performed at the time, and serial sectioning146
of the ovaries and tubes showed no tumor. She presented with a pelvic mass and147
ascites at age 50 and was diagnosed with a stage IIIc peritoneal carcinoma. As part of148
an epidemiologic study, the paraffin blocks of her BSO were subsequently step149
sectioned and revealed a STIC lesion. While a residual risk of primary peritoneal150
cancer of up to 4.3% has been reported in BRCA carriers following RRSO,[5] there is151
as yet insufficient evidence to indicate whether this risk is higher in women with STIC152
lesions and positive cytology and possibly even in those with STIC alone. This has153
implications for counselling and follow-up of this sub-group of patients.154
155
Limitations to our findings include a lack of central pathology review, incomplete156
data on staging in some series, absence of well-defined pathology protocols in some157
initial series and evolving terminology over a period of time. It is possible that the158
number of occult insitu / invasive lesions may be an underestimate of the true159
prevalence.160
Conclusion161
Available data suggest that the majority of occult invasive/ insitu cancers reported in162
women undergoing RRSO are early stage invasive/ insitu lesions. In the former163
situation, peritoneal cytology is mandatory for staging and subsequent decision164
regarding chemotherapy. It would be helpful if publications on RRSO specifically165
reported peritoneal cytology findings. Based on the available literature, we advocate166
that peritoneal washings should be part of the routine RRSO surgical protocol for167
high-risk women. The management of women with STIC remains a clinical dilemma.168
It is unknown whether these women (particularly with positive cytology) would169
represent a sub-group at higher risk who may need adjuvant therapy and closer170
follow-up. Given the low incidence of such cases at risk reducing surgery, there is a171
need for an international register to collect long term data on these patients and172
develop an evidence base to inform clinical practice/future research. The Pelvic-173
Ovarian Cancer Interception (POINT) Project[25] is an effort aimed at furthering the174
understanding of the frequency and outcome of these lesions.175
176
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TABLE LEGENDS
Table 1: Occult Stage 1 invasive cancers (with or without concomitant STIC)# detected at
RRSO
#Includes those cases with histology reports of invasive ovarian and fallopian tube cancer (with or
without concomitant STIC)
*Follow up data previously unpublished (personal communication)
BSO- bilateral salpingo-oophorectomy, C- Carboplatin, ca- cancer, CIS- carcinoma insitu, dis-
disease, FU- follow up, FTC- fallopian tube cancer, mth- months, NA- not available, Neg- negative,
Pos- positive, P- Paclitaxel, rec- recurrence, RAH- radical abdominal hysterectomy, STIC Serous
tubal carcinoma insitu, TAH- total abdominal hysterectomy, TLH- total laparoscopic hysterectomy,
T- Taxotere
Table 2: Occult carcinoma insitu (CIS) / Serous tubal insitu carcinoma (STIC) lesions#
(without concomitant invasion) detected at RRSO
#includes cases where the final histological diagnosis is STIC without concomitant invasive cancer
*Follow up data previously unpublished (personal communication)
BSO- bilateral salpingo-oophorectomy, bx- biopsy, C- Carboplatin, ca- cancer, CIS- carcinoma
insitu, dis- disease, FU- follow up, FTC- fallopian tube cancer, mth- months, NA- not available,
Neg- negative, Pos- positive, P- Paclitaxel, rec- recurrence, STIC Serous tubal carcinoma insitu,
TAH- total abdominal hysterectomy, T- Taxotere.
Table 3: Cases of Normal histology and positive cytology detected at RRSO
BSO- bilateral salpingo-oophorectomy, C- Carboplatin, dis- disease, mth- months, NA- not
available, Pos- positive, P- Paclitaxel, TAH- total abdominal hysterectomy
